Michael A Rosenberg

List of Publications by Year
in descending order

51 papers	2,492 citations	361413 20 h-index	265206 42 g-index
57 all docs	57 docs citations	57 times ranked	5227 citing authors

#	Article	IF	Citations
1	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	21.4	552
2	<scp>SIRT</scp>2 induces the checkpoint kinase BubR1 to increase lifespan. EMBO Journal, 2014, 33, 1438-1453.	7.8	195
3	Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. American Journal of Physiology - Cell Physiology, 2009, 297, 1124-1132.	4.6	168
4	Diastolic Dysfunction and Risk of Atrial Fibrillation. Circulation, 2012, 126, 2353-2362.	1.6	156
5	Use of a Noninvasive Continuous Monitoring Device in the Management of Atrial Fibrillation: A Pilot Study. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 328-333.	1.2	145
6	mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. American Journal of Physiology - Cell Physiology, 2010, 299, C1256-C1266.	4.6	118
7	Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. European Heart Journal, 2012, 33, 904-912.	2.2	114
8	Effects of myostatin deletion in aging mice. Aging Cell, 2009, 8, 573-583.	6.7	96
9	Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk. Circulation, 2017, 135, 1300-1310.	1.6	96
10	Pathological Role of Serum- and Glucocorticoid-Regulated Kinase 1 in Adverse Ventricular Remodeling. Circulation, 2012, 126, 2208-2219.	1.6	91
11	Ventricular Arrhythmia Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2009, 104, 128-132.	1.6	89
12	The impact of height on the risk of atrial fibrillation: the Cardiovascular Health Study. European Heart Journal, 2012, 33, 2709-2717.	2.2	89
13	Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation. JAMA Network Open, 2020, 3, e1919396.	5.9	76
14	The Nuclear Receptor Corepressor (NCoR) Controls Thyroid Hormone Sensitivity and the Set Point of the Hypothalamic-Pituitary-Thyroid Axis. Molecular Endocrinology, 2011, 25, 212-224.	3.7	73
15	B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. Heart Rhythm, 2014, 11, 1109-1116.	0.7	70
16	Measures of Body Size and Composition and Risk of Incident Atrial Fibrillation in Older People. American Journal of Epidemiology, 2016, 183, 998-1007.	3.4	35
17	Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS). American Heart Journal, 2014, 167, 723-728.e2.	2.7	33
18	Left ventricular sphericity independently predicts appropriate implantable cardioverter-defibrillator therapy. Heart Rhythm, 2016, 13, 490-497.	0.7	30

#	Article	IF	Citations
19	Applications of machine learning in decision analysis for dose management for dofetilide. PLoS ONE, 2019, 14, e0227324.	2.5	25
20	Genetic Variants Related to Height and Risk of Atrial Fibrillation. American Journal of Epidemiology, 2014, 180, 215-222.	3.4	24
21	Taller height as a risk factor for venous thromboembolism: a Mendelian randomization meta‐analysis. Journal of Thrombosis and Haemostasis, 2017, 15, 1334-1343.	3.8	19
22	Interlead heterogeneity of R‐ and T‐wave morphology in standard 12‐lead ECGs predicts sustained ventricular tachycardia/fibrillation and arrhythmic death in patients with cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2017, 28, 1324-1333.	1.7	19
23	Serum androgens and risk of atrial fibrillation in older men: The Cardiovascular Health Study. Clinical Cardiology, 2018, 41, 830-836.	1.8	18
24	Validation of Polygenic Scores for QT Interval in Clinical Populations. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	17
25	A Novel Transgenic Mouse Model of Cardiac Hypertrophy and Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 4, 415.	0.5	17
26	Height and risk of sudden cardiac death: the Atherosclerosis Risk in Communities and Cardiovascular Health Studies. Annals of Epidemiology, 2014, 24, 174-179.e2.	1.9	16
27	Frailty, Implantable Cardioverter Defibrillators, and Mortality: a Systematic Review. Journal of General Internal Medicine, 2019, 34, 2224-2231.	2.6	15
28	Prediction of incident myocardial infarction using machine learning applied to harmonized electronic health record data. BMC Medical Informatics and Decision Making, 2020, 20, 252.	3.0	13
29	Prediction of Drug-Induced Long QT Syndrome Using Machine Learning Applied to Harmonized Electronic Health Record Data. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 335-340.	2.0	13
30	Device-measured physical activity data for classification of patients with ventricular arrhythmia events: A pilot investigation. PLoS ONE, 2018, 13, e0206153.	2.5	10
31	Trusting Magic. Circulation, 2021, 143, 1299-1301.	1.6	10
32	Multicenter Analysis of Dosing Protocols for Sotalol Initiation. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 212-218.	2.0	9
33	Follow-Up After Catheter Ablation of Papillary Muscles and Valve Cusps. JACC: Clinical Electrophysiology, 2019, 5, 1185-1196.	3.2	8
34	Use of cell phone adapters is associated with reduction in disparities in remote monitoring of cardiac implantable electronic devices. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 469-475.	1.3	7
35	Esophageal position, measured luminal temperatures, and risk of atrioesophageal fistula with atrial fibrillation ablation. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 458-463.	1.2	6
36	Machine Learning Methodologies for Prediction of Rhythm-Control Strategy in Patients Diagnosed With Atrial Fibrillation: Observational, Retrospective, Case-Control Study. JMIR Medical Informatics, 2021, 9, e29225.	2.6	5

#	Article	IF	Citations
37	Assessing Prescriber Behavior with a Clinical Decision Support Tool to Prevent Drug-Induced Long QT Syndrome. Applied Clinical Informatics, 2021, 12, 190-197.	1.7	5
38	The Estimated Risk of Atrial Fibrillation Related to Alcohol Consumption. Journal of Atrial Fibrillation, 2012, 5, 424.	0.5	4
39	Assessment of a Mobile Health iPhone App for Semiautomated Self-management of Chronic Recurrent Medical Conditions Using an N-of-1 Trial Framework: Feasibility Pilot Study. JMIR Formative Research, 2022, 6, e34827.	1.4	2
40	Prevalence and Outcomes of Patients Receiving Implantable Cardioverter-Defibrillators for Primary Prevention Not Based on Guidelines. American Journal of Cardiology, 2015, 115, 1539-1544.	1.6	1
41	Feasibility of Frailty Assessment Integrated with Cardiac Implantable Electronic Device Clinic Follow-up: A Pilot Investigation. Gerontology and Geriatric Medicine, 2021, 7, 233372142098734.	1.5	1
42	Qualitative Evaluation of an Artificial Intelligence–Based Clinical Decision Support System to Guide Rhythm Management of Atrial Fibrillation: Survey Study. JMIR Formative Research, 2022, 6, e36443.	1.4	1
43	To the Editor—Spontaneous conversion of a long RP to short RP tachycardia: what is the mechanism?. Heart Rhythm, 2014, 11, E5.	0.7	0
44	Lowering the Risk for Thrombus and Stroke in Atrial Fibrillation Patients: Will Dabigatran Replace Warfarin?. Clinical Medicine Reviews in Vascular Health, 2013, 5, 1-8.	3.0	0
45	Circulating Fibrosis Biomarkers and Cardiovascular Health: Disease-Focused Approach in Heart Failure, Arrhythmias, Sudden Cardiac Death, and Atrial Fibrillation. , 2015, , 1-34.		0
46	Disease Focused Approach on Fibrosis Biomarkers in Cardiovascular Health. , 2016, , 601-634.		0
47	Disease Focused Approach on Fibrosis Biomarkers in Cardiovascular Health. , 2016, , 1-34.		0
48	Applications of machine learning in decision analysis for dose management for dofetilide. , 2019, 14, e0227324.		0
49	Applications of machine learning in decision analysis for dose management for dofetilide. , 2019, 14, e0227324.		0
50	Applications of machine learning in decision analysis for dose management for dofetilide. , 2019, 14, e0227324.		0
51	Applications of machine learning in decision analysis for dose management for dofetilide. , 2019, 14, e0227324.		0